GlassScriptPhysician profile
Noelle Brossman
NPI 1558824854
$2,024.82
in general payments reported to CMS, 2019-2025
18 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.15 · 2022: $19.94 · 2023: $263 · 2024: $71.12 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.73 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.30 | 2025 | |
| Madrigal Pharmaceuticals | $288.48 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $266.40 | 2025 | Tremfya |
| Sumitomo Pharma America, INC. | $232.11 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $196.64 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.80 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.87 | 2025 | Xifaxan |
| Boston Scientific Corporation | $55.44 | 2022-2023 | Uromax Ultra, Lithovue |
| Phathom Pharmaceuticals, INC. | $53.60 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $49.14 | 2025 | Dupixent |
| Qol Medical, LLC | $41.98 | 2025 | Sucraid |
| Novo Nordisk INC | $31.13 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $21.81 | 2025 | Iqirvo |
| Endo Pharmaceuticals INC. | $19.86 | 2023 | Xiaflex |
| Axonics, INC. | $19.51 | 2024 | Axonics |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15.19 | 2025 | |
| Urogen Pharma, INC. | $14.41 | 2023 | Jelmyto |
| Genentech USA, INC. | $3.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Brossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.